Weihai Municipal Hospital, Weihai, 264200, P. R. China.
J Microbiol. 2018 Dec;56(12):886-892. doi: 10.1007/s12275-018-8152-x. Epub 2018 Nov 27.
Statin response shows great interindividual variations. Recently, emerging studies have shown that gut microbiota is linked to therapeutic responses to drugs, including statins. However, the association between the gut bacteria composition and statin response is still unclear. In this study, gut microbiota of 202 hyperlipidemic patients with statin sensitive (SS) response and statin resistant (SR) response in East China were investigated by high throughput sequencing to compare the gut bacteria composition and biodiversity in distinct statin response patients. Higher biodiversity was detected in Group SS than Group SR. Specifically, group SS showed significantly increased proportion of genera Lactobacillus (P = 0.001), Eubacterium (P = 0.004), Faecalibacterium (P = 0.005), and Bifidobacterium (P = 0.002) and decreased proportion of genus Clostridium (P = 0.001) compared to Group SR. The results indicated that higher gut biodiversity was associated with statin sensitive response. The increased genera Lactobacillus, Eubacterium, Faecalibacterium, Bifidobacterium, and decreased genus Clostridium in patient gut microbiota may predict patient's statin response, and hence may guide statin dosage adjustments.
他汀类药物反应存在很大的个体差异。最近的研究表明，肠道微生物群与药物（包括他汀类药物）的治疗反应有关。然而，肠道细菌组成与他汀类药物反应之间的关联尚不清楚。在这项研究中，通过高通量测序研究了华东地区 202 例高脂血症患者的肠道微生物群，这些患者对他汀类药物敏感（SS）和他汀类药物耐药（SR）。结果表明，与 SR 组相比，SS 组的多样性更高。具体而言，与 SR 组相比，SS 组的乳杆菌属（P=0.001）、真杆菌属（P=0.004）、粪杆菌属（P=0.005）和双歧杆菌属（P=0.002）比例显著增加，而梭菌属（P=0.001）比例显著降低。这些结果表明，较高的肠道微生物多样性与他汀类药物敏感反应有关。患者肠道微生物群中乳杆菌属、真杆菌属、粪杆菌属、双歧杆菌属的增加和梭菌属的减少可能预测患者的他汀类药物反应，从而可能指导他汀类药物剂量的调整。
